Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing
Cytopathology · 2023
DOI: 10.1111/cyt.13295 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cytopathology, 2023. Verfasst von Alberto Ranghiero und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Breast Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer biomarker profiling predominantly relies on tissue testing (surgical and/or biopsy samples). However, the field of liquid biopsy, particularly the analysis of circulating tumour DNA (ctDNA), has witnessed remarkable progress and continues to evolve rapidly. The incorporation of ctDNA‐based testing into clinical practice is creating new opportunities for patients with metastatic breast cancer (MBC). ctDNA offers advantages over conventional tissue analyses, as it reflects tumour heterogeneity and enables multiple serial biopsies in a minimally invasive manner. Thus, it serves as a valuable complement to standard tumour tissues and, in certain instances, may even present a potential alternative approach. In the context of MBC, ctDNA testing proves highly informative in the detection of disease progression, monitoring treatment response, assessing actionable biomarkers, and identifying mechanisms of resistance. Nevertheless, ctDNA does exhibit inherent limitations, including its generally low abundance, necessitating timely blood samplings and rigorous management of the pre‐analytical phase. The development of highly sensitive assays and robust bioinformatic tools has paved the way for reliable ctDNA analyses. The time has now come to establish how ctDNA and tissue analyses can be effectively integrated into the diagnostic workflow of MBC to provide patients with the most comprehensive and accurate profiling. In this manuscript, we comprehensively analyse the current methodologies employed in ctDNA analysis and explore the potential benefits arising from the integration of tissue and ctDNA testing for patients diagnosed with MBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- School of Pathology, University of Milan, Milan, Italy.
ORCID-Profile: Mariia Ivanova, Konstantinos Venetis
Zitieren
APA
Ranghiero, A., Frascarelli, C., Cursano, G., Pescia, C., Ivanova, M., Vacirca, D., Rappa, A., Taormina, S. V., Barberis, M., Fusco, N., Rocco, E. G., & Venetis, K. (2023). Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing. Cytopathology. https://doi.org/10.1111/cyt.13295
Vancouver
Ranghiero A, Frascarelli C, Cursano G, Pescia C, Ivanova M, Vacirca D, et al. Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing. Cytopathology. 2023. doi:10.1111/cyt.13295
BibTeX
@article{Ranghiero2023,
author = {Ranghiero, Alberto and Frascarelli, Chiara and Cursano, Giulia and Pescia, Carlo and Ivanova, Mariia and Vacirca, Davide and Rappa, Alessandra and Taormina, Sergio Vincenzo and Barberis, Massimo and Fusco, Nicola and Rocco, Elena Guerini and Venetis, Konstantinos},
title = {Circulating tumour DNA testing in metastatic breast cancer: Integration with tissue testing},
journal = {Cytopathology},
year = {2023},
doi = {10.1111/cyt.13295}
}
EUVIMED